Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.

Original languageEnglish (US)
Pages (from-to)3037
Number of pages1
JournalOncogene
Volume41
Issue number21
DOIs
StatePublished - May 20 2022

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)'. Together they form a unique fingerprint.

Cite this